Summit Therapeutics (SMMT) Payables (2018 - 2026)

Summit Therapeutics (SMMT) has 9 years of Payables data on file, last reported at $22.9 million in Q2 2026.

• Quarterly Payables changed 0.37% year-over-year to $22.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.9 million (changed 0.37% YoY) and the FY2025 annual result came in at $20.3 million, up 337.7% from the prior year.
• Payables retreated to $22.9 million in Q2 2026, from $27.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $103.3 million in Q2 2024 to a low of $710000.0 in Q1 2023.
• A 5-year average of $22.4 million and a median of $13.5 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables plunged 89.8% — and 2024, when it surged 10370.11%.
• Tracing SMMT's Payables over 5 years: stood at $20.1 million in 2022, then slumped by 86.75% to $2.7 million in 2023, then surged by 73.83% to $4.6 million in 2024, then jumped by 337.7% to $20.3 million in 2025, then increased by 12.83% to $22.9 million in 2026.
• The last three Payables figures came in at $22.9 million (Q2 2026), $27.5 million (Q1 2026), and $20.3 million (Q4 2025), per Business Quant data.